The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Plant-based Biologics and Expression Systems Market by Type of Product (Biosimilars, Cell Therapies, Gene Therapies, Monoclonal Antibodies, Vaccines and Others), Type of Plant (Algae, Barley, Benth, Duckweed, Lettuce, Maize, Moss, Rice, Tomato, Tobacco and Wheat Germ), Type of Expression System (Stable Expression System and Transient Expression System), Type of Target Disease Indication (Cirrhotic Ascites, COVID-19, Cystic Fibrosis, Ebola Virus Infection, Fabry Disease, Gaucher Disease, Liver Cirrhosis, Influenza, and Peanut Allergy), Type of Therapeutic Area (Genetic Disorders, Infectious Disorders, Liver Disorders, Respiratory Disorders and Others), Drug (Elelyso, PALFORZIA, OsrHSA, PRX-102, Unnamed_1, Unnamed_2, PRX-110 and ZMapp), Region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World)

  • Lowest Price Guaranteed From USD 5,899

  • Published
    February 2022

  • Slides
    155

  • View Count
    796

Example Insights

Plant-based-Biologics-and-Expression-Systems-Market-Context Plant-based-Biologics-and-Expression-Systems-Market-System-Providers Plant-based-Biologics-and-Expression-Systems-Market-Expression-Systems Plant-based-Biologics-and-Expression-Systems-Market-Small-Companies
Plant-based-Biologics-and-Expression-Systems-Market-Drug-Candidates Plant-based-Biologics-and-Expression-Systems-Market-Status-of-Development Plant-based-Biologics-and-Expression-Systems-Market-Key-Examples Plant-based-Biologics-and-Expression-Systems-Market-Publication-Analysis
Plant-based-Biologics-and-Expression-Systems-Market-Growth-Scenarios Plant-based-Biologics-and-Expression-Systems-Market-Type-of-Service Plant-based-Biologics-and-Expression-Systems-Market-Disease-Indication  

 

Overview

At present, biotechnology companies are on the look-out for cost-effective solutions such as plant-based expression systems, in order to support their research and manufacturing initiatives

-- Chief Project Manager, Business Development & Co-Founder, Europe-based mid-sized Company

A significant rise in the popularity of biologics has been observed over the years. The demand for such treatment modalities further witnessed a surge post the onset of the COVID-19 pandemic. At present, about 85% of the drug candidates are produced using mammalian cell cultures. However, such systems are associated with a number of challenges; these include risk of introducing pathogens, concerns related to scale-up, decrease in productivity and rise in byproduct formation. It is also worth highlighting that research indicates that the existing mammalian cell capacities are likely to fulfill only 50% of the inflated demand (due to COVID-19) for biologics. In this context, owing to some major advances in synthetic organic chemistry, plant based expression systems have emerged as a promising alternative for the development of biologics. It is worth mentioning that plant-host engineering allows the production of proteins with distinct and uniform post-translational modifications, allowing the development of biologics, which demonstrate higher effectiveness, as compared to those produced using other protein expression systems, such as mammalian or yeast-based cell cultures. Plant-based biologics are safer, as they pose negligible risk of introducing human and animal pathogens in the therapy candidates. Additionally, plant molecular farming has the ability to facilitate rapid (4-8 weeks) plant-based biologics manufacturing at a large scale (several grams), as well as to meet the emergency demands (as observed in the case of COVID-19 pandemic). Moreover, the running costs of a GMP plant-based manufacturing facility are reported to be 25% less than those using other expression systems.

Given the aforementioned factors, pharmaceutical players are actively adopting plant-based expression systems for the production of various recombinant proteins. A wide range of vaccine candidates, plant-based enzymes, therapeutic proteins (including monoclonal antibodies) and nutritional proteins have also been produced via transgenic and transient expression in entire plants or plant cell cultures. Currently, close to 50 plant-based therapies have been developed / are being evaluated and more than 35 plant-based expression system providers are actively offering their proprietary technologies to drug developers. Multiple partnerships between industry and non-industry stakeholders, focused on the development of plant-based therapies, have been established. Driven by increasing prevalence of disease indications, growing demand for biologics, the ongoing efforts being carried out to advance the development of such products, as well as further optimize the associated technologies, the global plant-based biologics market is likely to grow at a healthy rate, in the foreseen future.

Scope of the Report

The “Plant-based Biologics and Expression Systems Market by Type of Product (Biosimilars, Cell Therapies, Gene Therapies, Monoclonal Antibodies, Vaccines and Others), Type of Plant (Algae, Barley, Benth, Duckweed, Lettuce, Maize, Moss, Rice, Tomato, Tobacco and Wheat Germ), Type of Expression System (Stable Expression System and Transient Expression System), Type of Target Disease Indication (Cirrhotic Ascites, COVID-19, Cystic Fibrosis, Ebola Virus Infection, Fabry Disease, Gaucher Disease, Liver Cirrhosis, Influenza, and  Peanut Allergy), Type of Therapeutic Area (Genetic Disorders, Infectious Disorders, Liver Disorders, Respiratory Disorders and Others), Drug (Elelyso, PALFORZIA, OsrHSA,  PRX-102, Unnamed_1, Unnamed_2, PRX-110 and ZMapp), and  Region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of plant-based therapies in the pharmaceutical industry, over the next 13 years. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

  • A detailed overview of the current market landscape of plant-based expression system providers, including information on some relevant parameters such as the type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco, and wheat germ), type of product (antibodies (unspecified), biosimilars, cell therapies, gene therapies, monoclonal antibodies, proteins (unspecified), vaccines and others), and type of expression system (transient and stable). Additionally, it highlights information on plant-based expression system providers, including details related to their respective year of establishment, company size (in terms of employee count), location of headquarters and number of proprietary technologies.
  • A detailed overview of the current market landscape of plant-based biologics, including information on their status of development (marketed, clinical and preclinical), target disease indication (cirrhotic ascites, COVID-19, cystic fibrosis, Ebola virus infection, Fabry disease, Gaucher Disease, liver cirrhosis, influenza, and  peanut allergy), therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders, and others) and type of product (antibodies (unspecified), biosimilars, cell therapies, monoclonal antibodies, proteins (unspecified), vaccines and others). Additionally, it highlights the developers of these novel therapeutics, including details on their year of establishment, company size (in terms of employee count), location of headquarters and number of proprietary drug candidates.
  • Elaborate profiles of key players engaged in providing plant-based expression system technologies to drug developers. Each profile features a brief overview of the company, details related to its technology portfolio, recent developments, and an informed future outlook.
  • An analysis of the recent partnerships and collaborations that have been inked between various stakeholders in the domain, during the period between 2017 and 2021, covering R&D agreements, licensing agreements, commercialization agreements, product development agreements, product development and manufacturing agreement, acquisitions and others. 
  • An insightful company competitiveness analysis, including a 2*2 matrix comparing the key players engaged in offering plant-based expression systems, based on several relevant parameters (such as company experience, portfolio strength, partnership activity and company size). It also includes a benchmarking analysis of systems providers based on their portfolio strength and partnership activity.
  • An insightful publication analysis, which includes analysis of more than 1,000 peer-reviewed scientific articles related to plant-based biologics, published between 2000-2021, highlighting the research focus within this niche industry segment. Additionally, it features key trends observed across the aforementioned publications, including analysis based on several relevant parameters, such as year of publication, type of article, journal title, primary funding body, publisher, primary author, journal impact factor and key timelines. Further, it includes a multivariate publication attractiveness analysis based on various parameters, such as type of article, grant support, journal impact factor and timeline of publications.

One of the key objectives of the report was to estimate the existing size and the future opportunity associated with the plant-based biologics and expression systems market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates, expected pricing and R&D expenditure, we have provided informed estimates on the financial evolution of the market for the period 2022-2035. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of product (biosimilars, cell therapies, gene therapies, monoclonal antibodies, vaccines and others [B] type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco and wheat germ), [C] type of expression system (stable expression system and transient expression system) [D] target disease indication (cirrhotic ascites, COVID-19, cystic fibrosis, Ebola virus infection, Fabry disease, Gaucher disease, liver cirrhosis, influenza, and  peanut allergy) [E] therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders and others) [F] drug (Elelyso, OsrHSA, PALFORZIA, PRX-110, PRX-102, Unnamed_1, Unnamed_2 and ZMapp) and [G] region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World). In order to account for future uncertainties and to add robustness to our forecast model, we have provided three forecast scenarios, portraying the conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified

Key Questions Answered

  • Who are the key players engaged in providing plant-based expression systems?
  • What are the key plant sources utilized by drug developers to manufacture plant-based biologics?
  • Which are the key therapeutic areas for which plant-based biologics are being developed?
  • What are the different proprietary technologies of plant-based expression system providers?
  • What type of partnership models are most commonly adopted by stakeholders engaged in this domain?
  • What is the relative competitiveness of different plant-based expression system providers?
  • What is the evolving trend related to the focus of publications related to plant-based biologics?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of plant-based biologics and expression systems market and its likely evolution in the coming future.

Chapter 3 is an introductory chapter that highlights important concepts related to plant-based expression system providers. The chapter features information on classification of plant-based expression platforms and their associated advantages. Additionally, it includes a discussion on the commonly used plant-based bioproduction systems and mechanism of plant expression platforms. Further, it features details related to several recent developments observed in this domain.

Chapter 4 includes information on more than 35 plant-based expression system providers. It features a detailed analysis on current market landscape of plant-based expression system providers, including type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco, and wheat germ), type of product, and type of expression system (transient and stable). Additionally, the chapter features developers’ landscape, along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters and number of proprietary technologies.

Chapter 5 includes information on more than 45 plant-based biologics. It features a detailed analysis on current market landscape of plant-based biologics, including information on status of development (marketed, clinical and preclinical), target disease indication, therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders, and others), type of product (antibodies (unspecified), biosimilars, cell therapies, monoclonal antibodies, proteins (unspecified), vaccines and others). The chapter also features developers’ landscape, along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters and number of proprietary drug candidates.

Chapter 6 features elaborate profiles of the prominent players engaged in providing plant-based expression system technologies to drug developers. Each profile features a brief overview of the company, details related to technology portfolio, recent developments, and an informed future outlook.

Chapter 7 presents an analysis on recent collaborations and partnerships that have been inked by several stakeholders in this domain, during the period 2017-2021, covering R&D agreements, licensing agreements, commercialization agreements, product development agreements, product development and manufacturing agreement, acquisitions, and others.

Chapter 8 presents a detailed company competitiveness analysis, including a 2*2 matrix comparing the key players engaged in the domain of plant-based expression systems, based on several relevant parameters (such as company experience, portfolio strength, partnership activity and company size). In addition, it features a spider web representation illustrating benchmarking of players based on portfolio strength and partnership activity of key players.

Chapter 9 presents an insightful analysis of more than 1,000 peer-reviewed scientific articles related to plant-based biologics, published between 2000-2021, highlighting the research focus within this niche industry segment. It also features, key trends observed across the aforementioned publications including analysis based on several relevant parameters, such as year of publication, type of article, journal title, primary funding body, publisher, primary author, journal impact factor and analysis based on timeline. Further, the chapter also highlights a multivariate publication attractiveness analysis based on various parameters such as type of article, grant support, journal impact factor and timeline of publications.

Chapter 10 presents a detailed market forecast analysis, highlighting the current market size and the future growth potential associated with plant-based expression system market, during the period 2022-2035. Additionally, the chapter provides the likely distribution of the current and forecasted opportunity based on type of product (biosimilars, cell therapies, gene therapies, monoclonal antibodies, vaccines, and others). type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco, and wheat germ), type of expression system (stable expression system and transient expression system), region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World).

Chapter 11 presents a detailed market forecast analysis, highlighting the current market size and the future growth potential associated with the plant-based biologics market, during the period 2022-2035. The chapter also provides the likely distribution of the current and forecasted opportunity based on type of target disease indication (cirrhotic ascites, COVID-19, cystic fibrosis, Ebola virus infection, Fabry disease, Gaucher disease, liver cirrhosis, influenza, and peanut allergy), type of therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders and others), drug (Elelyso, OsrHSA, PALFORZIA, PRX-110, PRX-102, Unnamed_1, Unnamed_2 and ZMapp) and region (North America, Europe, Asia and Rest of the World).

Chapter 12 is a collection of executive insights of the discussions that were held with various key stakeholders in this market.

Chapter 13 is an appendix, which provides tabulated data and numbers for all figures provided in the report. 

Chapter 14 is an appendix, which provides publications data and numbers for timeline analysis present in publications analysis chapter.

Chapter 15 is an appendix, which comprises of the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Plant-based Biologics and Expression Systems
3.2. Classification of Plant-based Expression Platforms
3.3. Mechanism of Plant Expression Platform 
3.4. Advantages Offered by Plant-based Bioproduction Systems 
3.5. Commonly used Plant-based Bioproduction Systems 
3.6. Key Developments 
3.7. Future Perspectives

4. PLANT-BASED EXPRESSION SYSTEMS: MARKET LANDSCAPE
4.1. Plant-based Expression Systems: Market Overview and Developer Landscape  
4.2. List of Plant-based Expression System Providers
4.2.1. Analysis by Type of Plant
4.2.2. Analysis by Type of Biologic
4.2.3. Analysis by Type of Plant and Type of Biologic
4.2.4. Analysis by Type of Biologic and Region
4.2.5. Analysis by Type of Plant, Type of Biologic and Region
4.2.6. Analysis by Type of Service
4.2.7. Analysis by Year of Establishment
4.2.8. Analysis by Company Size
4.2.9. Analysis by Region (Country-wise)
4.2.10. Analysis by Region (Continent-wise)

5. PLANT-BASED BIOLOGICS: MARKET LANDSCAPE
5.1. Plant-based Biologics: Pipeline Review and Developer Landscape  
5.2. List of Drug Candidates 
5.2.1. Analysis by Status of Development
5.2.2. Analysis by Target Disease Indication
5.2.3. Analysis by Therapeutic Area
5.2.4. Analysis by Status of Development and Therapeutic Area
5.2.5. Analysis by Type of Biologic
5.2.6. Analysis by Status of Development and Type of Product

5.3. Plant-based Biologics: List of Drug Developers 
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Region
5.3.3.1. Analysis of Players in North America
5.3.3.2. Analysis of Players in Europe
5.3.3.3. Analysis of Players in Asia and Rest of the World

6. COMPANY PROFILES
6.1. Medicago
6.1.1. Company Overview
6.1.2. Technology Portfolio
6.2.3. Recent Developments and Future Outlook

6.2. Leaf Expression Systems
6.2.1. Company Overview
6.2.2. Technology Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Eleva
6.3.1. Company Overview
6.3.2. Technology Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. iBIO
6.4.1. Company Overview
6.4.2. Technology Portfolio
6.4.3. Recent Developments and Future Outlook

6.5. PlantForm
6.5.1. Company Overview
6.5.2. Technology Portfolio
6.5.3. Recent Developments and Future Outlook

6.6. G+Flas Life Sciences
6.6.1. Company Overview
6.6.2. Technology Portfolio
6.6.3. Recent Developments and Future Outlook

6.7. Kentucky Bioprocessing
6.7.1. Company Overview
6.7.2. Technology Portfolio
6.7.3. Recent Developments and Future Outlook

6.8. Angany
6.8.1. Company Overview
6.8.2. Technology Portfolio
6.8.3. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
7.1.  Plant-based Biologics and Expression Systems: Partnerships and Collaborations
7.1.1. Analysis by Cumulative Year-wise Trend of Partnerships 
7.1.2. Analysis by Type of Partnership
7.1.3. Analysis by Year and Type of Partnership
7.1.4. Analysis by Type of Biologic
7.1.5. Analysis by Type of Partnership and Type of Biologic
7.1.6. Key Players: Analysis by Number of Partnerships
7.1.7. Analysis by Partner Headquarters (Region)
7.1.8. Analysis by Region and Type of Agreement
7.1.9. Intercontinental and Intracontinental Partnerships

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Plant-based Expression System Providers: Company Competitiveness Analysis
8.1.1. Assumptions and Key Parameters
8.1.2. Methodology
8.3. Benchmarking of Portfolio Strength
8.4. Benchmarking of Partnership Strength
8.5. Company Competitiveness Analysis: Small Companies
8.6. Company Competitiveness Analysis: Mid-sized Companies
8.7. Company Competitiveness Analysis: Large Companies

9. PUBLICATIONS ANALYSIS
9.1. Plant-based Biologics and Expression Systems: Publications Analysis 
9.1.1. Analysis Methodology 
9.1.2. Key Parameters 
9.2. Analysis by Year of Publication 
9.3. Analysis by Type of Publication
9.4. Key Journals based on Publications Count 
9.5. Analysis by Primary Author 
9.6. Analysis by Publisher 
9.7. Analysis by Primary Funding Body 
9.8. Analysis by Journal Impact Factor 
9.9. Analysis by Key Journals and Journal Impact Factor 
9.10. Word Cloud: Emerging Focus Area 
9.11. Timeline Analysis  
9.11.1. Analysis by Article Type and Timeline of Receipt, Acceptance and ApprovalAnalysis by Article Type and Timeline of Receipt, Acceptance and Approval 
9.11.2. Analysis by Journal Impact Factor and Timeline of Receipt, Acceptance and ApprovalAnalysis by Journal Impact Factor and Timeline of Receipt, Acceptance and Approval 
9.11.3. Analysis by Grant Awarded and Timeline of Receipt, Acceptance and Approval 
9.12. Benchmarking Methodology
9.13. Benchmarking Analysis
9.14. List of Top 50 Publications

10. PLANT-BASED EXPRESSION SYSTEMS: MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Methodology and Key Assumptions 
10.2. Segments Forecasted 
10.3. Plant-based Expression Systems: Sales Forecast
10.4. Analysis by Type of Product: Global Sales Forecast, 2022 and 2035
10.4.1. Plant-based Expression Systems Market for Biosimilars, 2022-2035
10.4.2. Plant-based Expression Systems Market for Cell Therapies, 2022-2035
10.4.3. Plant-based Expression Systems Market for Gene Therapies, 2022-2035
10.4.4. Plant-based Expression Systems Market for Monoclonal Antibodies, 2022-2035
10.4.5. Plant-based Expression Systems Market for Vaccines, 2022-2035
10.4.6. Plant-based Expression Systems Market for Others, 2022-2035

10.5. Distribution by Type of Plant: Global Sales Forecast, 2022 and 2035
10.5.1. Plant-based Expression Systems Market for Algae, 2022-2035
10.5.2. Plant-based Expression Systems Market for Barley, 2022-2035
10.5.3. Plant-based Expression Systems Market for Benth, 2022-2035
10.5.4. Plant-based Expression Systems Market for Duckweed, 2022-2035
10.5.5. Plant-based Expression Systems Market for Lettuce, 2022-2035
10.5.6. Plant-based Expression Systems Market for Maize, 2022-2035
10.5.7. Plant-based Expression Systems Market for Moss, 2022-2035
10.5.8. Plant-based Expression Systems Market for Rice, 2022-2035
10.5.9. Plant-based Expression Systems Market for Tomato, 2022-2035
10.5.10. Plant-based Expression Systems Market for Tobacco, 2022-2035
10.5.11. Plant-based Expression Systems Market for Wheat Germ, 2022-2035

10.6. Analysis by Type of Expression System: Global Sales Forecast, 2022 and 2035
10.6.1. Plant-based Expression Systems Market for Stable Expression System, 2022-2035
10.6.2. Plant-based Expression Systems Market for Transient Expression System,2022-2035

10.7. Analysis by Region: Global Sales Forecast, 2022 and 2035
10.7.1. Plant-based Expression Systems Market in North America, 2022-2035
10.7.2. Plant-based Expression Systems Market in Europe, 2022-2035
10.7.3. Plant-based Expression Systems Market in Asia, 2022-2035
10.7.4. Plant-based Expression Systems Market in Latin America, 2022-2035
10.7.5. Plant-based Expression Systems Market in MENA, 2022-2035
10.7.6. Plant-based Expression Systems Market in Rest of the World, 2022-2035

11. PLANT-BASED BIOLOGICS: MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. List of Forecasted DrugsKey Parameters and Assumptions
11.2. List of Forecasted DrugsAnalysis Methodology 
11.3. List of Forecasted Drugs
11.3.1. Elelyso, Protalix Biotherapeutics
11.3.1.1. Global Sales Forecast
11.3.1.2. Regional Sales Forecast
11.3.1.3. Net Present Value
11.3.1.4. Value Creation Analysis

11.3.2. PALFORZIA, Aimmune Therapeutics
11.3.2.1. Global Sales Forecast
11.3.2.2. Regional Sales Forecast
11.3.2.3. Net Present Value
11.3.2.4. Value Creation Analysis

11.3.3. OsrHSA, Healthgen Biotechnology
11.3.3.1. Global Sales Forecast
11.3.3.2. Regional Sales Forecast
11.3.3.3. Net Present Value
11.3.3.4. Value Creation Analysis

11.3.4. PRX-102, Protalix Biotherapeutics
11.3.4.1. Global Sales Forecast
11.3.4.2. Regional Sales Forecast
11.3.4.3. Net Present Value
11.3.4.4. Value Creation Analysis

11.3.5. Unnamed_1, Medicago
11.3.5.1. Global Sales Forecast
11.3.5.2. Regional Sales Forecast
11.3.5.3. Net Present Value
11.3.5.4. Value Creation Analysis

11.3.6. Unnamed_2, Medicago
11.3.6.1. Global Sales Forecast
11.3.6.2. Regional Sales Forecast
11.3.6.3. Net Present Value
11.3.7.4. Value Creation Analysis

11.3.7. PRX-110, Protalix Biotherapeutics
11.3.7.1. Global Sales Forecast
11.3.7.2. Regional Sales Forecast
11.3.7.3. Net Present Value
11.3.7.4. Value Creation Analysis

11.3.8. ZMapp, Mapp Biopharmaceutical
11.3.8.1. Global Sales Forecast
11.3.8.2. Regional Sales Forecast
11.3.8.3. Net Present Value
11.3.8.4. Value Creation Analysis

11.4. Global Plant-based Biologics Market: Analysis by Target Disease Indication, 2022 and 2035
11.4.1. Plant-based Biologics Market for Cirrhotic Ascites, 2022-2035
11.4.2. Plant-based Biologics Market for COVID-19, 2022-2035
11.4.3 Plant-based Biologics Market for Cystic Fibrosis, 2022-2035
11.4.4 Plant-based Biologics Market for Ebola Virus Infection, 2022-2035
11.4.5. Plant-based Biologics Market for Fabry Disease, 2022-2035
11.4.6. Plant-based Biologics Market for Gaucher Disease, 2022-2035
11.4.7. Plant-based Biologics Market for Influenza, 2022-2035
11.4.8. Plant-based Biologics Market for Liver Cirrhosis, 2022-2035
11.4.9. Plant-based Biologics Market for Peanut Allergy, 2022-2035

11.5. Plant-based Biologics Market: Analysis by Therapeutic Area, 2022 and 2035
11.5.1. Plant-based Biologics Market for Genetic Disorders, 2022-2035
11.5.2 Plant-based Biologics Market for Infectious Disorders, 2022-2035
11.5.3 Plant-based Biologics Market for Liver Disorders, 2022-2035
11.5.4. Plant-based Biologics Market for Respiratory Disorders, 2022-2035
11.5.5. Plant-based Biologics Market for Others, 2022-2035

11.6. Plant-based Biologics Market: Analysis by Region, 2022 and 2035
11.6.1. Plant-based Biologics Market in North America, 2022-2035
11.6.2. Plant-based Biologics Market in Europe, 2022-2035
11.6.3. Plant-based Biologics Market in Asia, 2022-2035
11.6.4. Plant-based Biologics Market in Rest of the World, 2022-2035

11.7. Plant-based Biologics: Overall Market Opportunity, 2022-2035
11.8. Plant-based Biologics: Market Share of Key Players
11.9. Plant-based Biologics: Regional Distribution, 2022,2028 and 2035
11.10. Region-wise Distribution (Bubble Chart Representation)

12. EXECUTIVE INSIGHTS
12.1. Transactiva
12.1.1. Company Snapshot
12.1.2. Interview Transcript: Sara Raccovelli (Researcher)

12.2. ORF Genetics
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Júlíus B Kristinsson (Chief Project Manager, Business Development & Co-Founder)

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 1: PUBLICATIONS DATA

15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Tables

Table 4.1 List of Plant-based Expression System Providers
Table 5.1 Plant-based Biologics: List of Drug Candidates
Table 5.2 Plant-based Biologics Developers: List of Drug Developers
Table 7.1 Plant-based Biologics and Expression Systems: Partnerships and Collaborations
Table 10.1 Global Plant-based Expression Systems Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.2 Plant-based Expression Systems Market: Analysis by Product, 2022 and 2035
Table 10.3 Plant-based Expression Systems Market for Biosimilars, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.4 Plant-based Expression Systems Market for Cell Therapies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.5 Plant-based Expression Systems Market for Gene Therapies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.6 Plant-based Expression Systems Market for Monoclonal Antibodies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.7 Plant-based Expression Systems Market for Vaccines, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.8 Plant-based Expression Systems Market for Others, Conservative, Base and Optimistic, 2022-2035 (USD Million)
Table 10.9 Plant-based Expression Systems Market: Analysis by Plant, 2022 and 2035
Table 10.10 Plant-based Expression Systems Market for Algae, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.11 Plant-based Expression Systems Market for Barley, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.12 Plant-based Expression Systems Market for Benth, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.13 Plant-based Expression Systems Market for Duckweed, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.14 Plant-based Expression Systems Market for Lettuce, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.15 Plant-based Expression Systems Market for Maize, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.16 Plant-based Expression Systems Market for Moss, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.17 Plant-based Expression Systems Market for Rice, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.18 Plant-based Expression Systems Market for Tomato, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.19 Plant-based Expression Systems Market for Tobacco, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.20 Plant-based Expression Systems Market for Wheat Germ, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.21 Plant-based Expression Systems Market: Analysis by Expression System, 2022 and 2035
Table 10.22 Plant-based Expression Systems Market for Stable Expression System,Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.23 Plant-based Expression Systems Market for Transient Expression System,Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.24 Plant-based Expression Systems Market: Analysis by Region, 2022 and 2035
Table 10.25 Plant-based Expression Systems Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.26 Plant-based Expression Systems Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.27 Plant-based Expression Systems Market in Asia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.28 Plant-based Expression Systems Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.29 Plant-based Expression Systems Market in MENA, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 10.30 Plant-based Expression Systems Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.1 List of Forecasted Drugs
Table 11.2 Elelyso, Protalix Biotherapeutics, Sales Forecast, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.3 PALFORZIA, Aimmune Therapeutics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.4 OsrHSA, Healthgen Biotechnology, Sales Forecast, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.5 PRX-102, Protalix Biotherapeutics, Sales Forecast, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.6 Unnamed_1, Medicago, Sales Forecast, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.7 Unnamed_2, Medicago, Sales Forecast, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.8 PRX-110, Protalix Biotherapeutics, Sales Forecast, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.9 ZMapp, Mapp Biopharmaceutical, Sales Forecast, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.10 Global Plant-based Biologics Market: Analysis by Target Disease Indication, 2022 and 2035
Table 11.11 Plant-based Biologics Market for Cirrhotic Ascites, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.12 Plant-based Biologics Market for COVID-19, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.13 Plant-based Biologics Market for Cystic Fibrosis, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.14 Plant-based Biologics Market for Ebola Virus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.15 Plant-based Biologics Market for Fabry Disease, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.16 Plant-based Biologics Market for Gaucher Disease, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.17 Plant-based Biologics Market for Influenza, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.18 Plant-based Biologics Market for Liver Cirrhosis, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.19 Plant-based Biologics Market for Peanut Allergy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.20 Plant-based Biologics Market: Analysis by Therapeutic Area, 2022 and 2035
Table 11.21 Plant-based Biologics Market for Genetic Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.22 Plant-based Biologics Market for Infectious Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.23 Plant-based Biologics Market for Liver Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.24 Plant-based Biologics Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.25 Plant-based Biologics Market for Others, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.26 Plant-based Biologics Market: Analysis by Region, 2022 and 2035
Table 11.27 Plant-based Biologics Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.28 Plant-based Biologics Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.29 Plant-based Biologics Market in Asia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 11.30 Plant-based Biologics Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. Agrenvec
  2. Angany
  3. Australian National University (ANU)
  4. atbtherapeutics
  5. AzarGen Biotechnologies
  6. Baiya Phytopharm
  7. BC Partners
  8. BGM Pharmaceuticals
  9. Bill and Melinda Gates Foundation 
  10. Bio-Manguinhos
  11. Oswaldo Cruz Foundation (Fiocruz)
  12. BioMed Central
  13. Caliber Biotherapeutics
  14. Cape Biologix Technologies
  15. Carnegie Corporation of New York 
  16. CC-Pharming (Also known as Ruicheng Haihui Biotechnology)
  17. CellFree Sciences
  18. Chiesi Farmaceutici
  19. Corteva Agriscience
  20. Council for Scientific and Industrial Research (CSIR)
  21. Creative Biolabs
  22. Defence Research & Development Canada
  23. Defyrus
  24. Dow AgroSciences
  25. Dynavax Technologies
  26. EdgePoint AI
  27. Eleva
  28. Elsevier
  29. ERS Genomics
  30. Eversea
  31. Fraunhofer Society
  32. Frontiers
  33. G+FLAS Life Sciences
  34. GenScript
  35. GlaxoSmithKline
  36. Government of Canada
  37. Healthgen Biotechnology
  38. HotHouse BioEngineering
  39. iBio
  40. Icon Genetics
  41. Inno-3B
  42. John Wiley and Sons
  43. Kentucky Bioprocessing
  44. Leaf Expression Systems
  45. LenioBio
  46. Lincoln Diagnostics
  47. Lung Biotechnology
  48. McMaster University
  49. MDPI
  50. Medicago
  51. National Collaborative Research Infrastructure Strategy 
  52. Australian Plant Phenomics Facility 
  53. National Institute of Allergy and Infectious Diseases
  54. National Institute of General Medical Sciences
  55. National Natural Science Foundation of China 
  56. Nature Publishing 
  57. National Institutes of Health 
  58. Nomad Bioscience
  59. ORF Genetics
  60. Oxford University Press
  61. PBL Technology 
  62. Pfizer
  63. Phylloceuticals
  64. PlantForm
  65. Poliomyelitis Research Foundation 
  66. POSCO 
  67. ProdiGene
  68. Profacgen
  69. Protalix Biotherapeutics
  70. Public Library of Science
  71. RubrYc Therapeutics
  72. Safi Biosolutions
  73. Samabriva
  74. SarcoMed USA
  75. Sigma-Aldrich
  76. Solarvest BioEnergy
  77. St George’s University of London
  78. Synthon
  79. Takara Bio
  80. Transactiva
  81. US Department of Defense 
  82. Unibio
  83. Universite? de Montre?al
  84. University of Alberta
  85. University of Guelph
  86. University of Wisconsin-Madison
  87. Ventria Bioscience
  88. Wilfrid Laurier University
  89. Zea Biosciences
  90. Zukunftsfonds Heilbronn

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com